LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: GlobeNewswire
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for LNZ100 for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. The FDA noted that it is not planning to hold an advisory committee meeting to discuss this application. “With the acceptance of our New Drug Application for LNZ100, we are pleased to be one step closer towards potential approval and look forward to continuing to collaborate with the FDA to deliver the first on
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- LENZ Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire
LENZ
Earnings
- 11/6/24 - Beat
LENZ
Sec Filings
- 12/17/24 - Form 4
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- LENZ's page on the SEC website